J Sex Med:盆腔骨折后的女性性功能障碍

2021-04-15 AlexYang MedSci原创

骨盆骨折(PFx)后的女性性功能障碍(FSD)在泌尿外科文献中很少引起关注。最近,有研究人员回顾和总结了目前有关女性PFx相关的性功能证据。

骨盆骨折(PFx)后的女性性功能障碍(FSD)在泌尿外科文献中很少引起关注。最近,有研究人员回顾和总结了目前有关女性PFx相关的性功能证据

研究人员按照PRISMA指南进行了系统性回顾,包括PubMed、EMBASE和MEDLINE数据库。研究人员只收录了有足够数据的英文手稿和摘要,并使用 "女性性功能障碍和骨盆骨折"、"性功能障碍和骨盆骨折 "和 "女性骨盆骨折和性功能障碍 "检索词进行搜索。

研究确定了177篇文章;回顾了41篇摘要。共15篇符合纳入标准并用于分析。研究的主要结果衡量指标是盆腔骨折后女性性功能障碍的发生率和类型。结果发现,FSD在PFx后普遍存在,报告的比例在25%至62%之间。3项研究使用了已验证的女性性功能指数。其他12项研究使用了未验证的问卷或改编的生活质量问卷,其中有关于FSD的具体问题。最常见的主诉包括性交困难、性感不快、性高潮功能障碍、生殖泌尿系统疼痛、性交兴趣下降、性交满意度下降和盆底功能障碍。只有1项研究涉及功能障碍的解决。

女性性功能障碍评估

最后,研究人员指出,创伤性PFx后的FSD并不罕见,多发生在年轻女性身上,而且可能是病态的泌尿外科文献中对PFx后FSD的报道不足。因此,所有女性PFx患者都应该通过已验证的问卷调查来筛查FSD。已发表的文献对PFx术后FSD的流行病学、评估、定义和可能的治疗方法报道甚少。因此,研究人员认为需要进行前瞻性研究来更好地了解创伤幸存者的女性性功能,以及预防和康复的可能方法

原始出处:

Alice B Walton, Gabriel Z Leinwand, Omer Raheem et al. Female Sexual Dysfunction After Pelvic Fracture: A Comprehensive Review of the Literature. J Sex Med. Mar 2021

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1665583, encodeId=ea5d16655834d, content=<a href='/topic/show?id=66134464223' target=_blank style='color:#2F92EE;'>#女性性功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44642, encryptionId=66134464223, topicName=女性性功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24e825973246, createdName=12498ef1m39(暂无昵称), createdTime=Sat Jul 03 10:37:00 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957538, encodeId=560895e5384e, content=三人行,必有我师。 <a href='/topic/show?id=d55f104233bd' target=_blank style='color:#2F92EE;'>#梅斯医学科研互助群#</a> 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104233, encryptionId=d55f104233bd, topicName=梅斯医学科研互助群)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/a7082efd72134f339011deffae56d660/9f9bdab2a00341ce92bf6fd196c67f81.png, createdBy=4e205474392, createdName=七安, createdTime=Fri Apr 16 10:33:36 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421360, encodeId=44ea14213605c, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sat Apr 17 13:37:00 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611003, encodeId=fee716110037e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Apr 17 13:37:00 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957523, encodeId=c8f395e5234b, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Fri Apr 16 10:25:00 CST 2021, time=2021-04-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1665583, encodeId=ea5d16655834d, content=<a href='/topic/show?id=66134464223' target=_blank style='color:#2F92EE;'>#女性性功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44642, encryptionId=66134464223, topicName=女性性功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24e825973246, createdName=12498ef1m39(暂无昵称), createdTime=Sat Jul 03 10:37:00 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957538, encodeId=560895e5384e, content=三人行,必有我师。 <a href='/topic/show?id=d55f104233bd' target=_blank style='color:#2F92EE;'>#梅斯医学科研互助群#</a> 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104233, encryptionId=d55f104233bd, topicName=梅斯医学科研互助群)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/a7082efd72134f339011deffae56d660/9f9bdab2a00341ce92bf6fd196c67f81.png, createdBy=4e205474392, createdName=七安, createdTime=Fri Apr 16 10:33:36 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421360, encodeId=44ea14213605c, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sat Apr 17 13:37:00 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611003, encodeId=fee716110037e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Apr 17 13:37:00 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957523, encodeId=c8f395e5234b, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Fri Apr 16 10:25:00 CST 2021, time=2021-04-16, status=1, ipAttribution=)]
    2021-04-16 七安

    三人行,必有我师。 #梅斯医学科研互助群# 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1665583, encodeId=ea5d16655834d, content=<a href='/topic/show?id=66134464223' target=_blank style='color:#2F92EE;'>#女性性功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44642, encryptionId=66134464223, topicName=女性性功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24e825973246, createdName=12498ef1m39(暂无昵称), createdTime=Sat Jul 03 10:37:00 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957538, encodeId=560895e5384e, content=三人行,必有我师。 <a href='/topic/show?id=d55f104233bd' target=_blank style='color:#2F92EE;'>#梅斯医学科研互助群#</a> 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104233, encryptionId=d55f104233bd, topicName=梅斯医学科研互助群)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/a7082efd72134f339011deffae56d660/9f9bdab2a00341ce92bf6fd196c67f81.png, createdBy=4e205474392, createdName=七安, createdTime=Fri Apr 16 10:33:36 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421360, encodeId=44ea14213605c, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sat Apr 17 13:37:00 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611003, encodeId=fee716110037e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Apr 17 13:37:00 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957523, encodeId=c8f395e5234b, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Fri Apr 16 10:25:00 CST 2021, time=2021-04-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1665583, encodeId=ea5d16655834d, content=<a href='/topic/show?id=66134464223' target=_blank style='color:#2F92EE;'>#女性性功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44642, encryptionId=66134464223, topicName=女性性功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24e825973246, createdName=12498ef1m39(暂无昵称), createdTime=Sat Jul 03 10:37:00 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957538, encodeId=560895e5384e, content=三人行,必有我师。 <a href='/topic/show?id=d55f104233bd' target=_blank style='color:#2F92EE;'>#梅斯医学科研互助群#</a> 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104233, encryptionId=d55f104233bd, topicName=梅斯医学科研互助群)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/a7082efd72134f339011deffae56d660/9f9bdab2a00341ce92bf6fd196c67f81.png, createdBy=4e205474392, createdName=七安, createdTime=Fri Apr 16 10:33:36 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421360, encodeId=44ea14213605c, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sat Apr 17 13:37:00 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611003, encodeId=fee716110037e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Apr 17 13:37:00 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957523, encodeId=c8f395e5234b, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Fri Apr 16 10:25:00 CST 2021, time=2021-04-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1665583, encodeId=ea5d16655834d, content=<a href='/topic/show?id=66134464223' target=_blank style='color:#2F92EE;'>#女性性功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44642, encryptionId=66134464223, topicName=女性性功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24e825973246, createdName=12498ef1m39(暂无昵称), createdTime=Sat Jul 03 10:37:00 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957538, encodeId=560895e5384e, content=三人行,必有我师。 <a href='/topic/show?id=d55f104233bd' target=_blank style='color:#2F92EE;'>#梅斯医学科研互助群#</a> 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104233, encryptionId=d55f104233bd, topicName=梅斯医学科研互助群)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/a7082efd72134f339011deffae56d660/9f9bdab2a00341ce92bf6fd196c67f81.png, createdBy=4e205474392, createdName=七安, createdTime=Fri Apr 16 10:33:36 CST 2021, time=2021-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421360, encodeId=44ea14213605c, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Sat Apr 17 13:37:00 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611003, encodeId=fee716110037e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Apr 17 13:37:00 CST 2021, time=2021-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957523, encodeId=c8f395e5234b, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Fri Apr 16 10:25:00 CST 2021, time=2021-04-16, status=1, ipAttribution=)]
    2021-04-16 ms3000000449926787

    已阅

    0

相关资讯

J Sex Med:女性性功能障碍影响了男性伴侣性功能!

FSD与男性性功能障碍(MSD)之间关系是一个关键的世界性健康问题。目前,FSD与MSD之间的相互关系仍然没有定论。

女用“PDE5抑制剂”即将问世:旨在帮助解决女性性功能障碍

位于荷兰的Emotional Brain公司已在940位患有女性性功能障碍(FSD)的女性中测试其实验性药物Lybrido,参与者一直在网上保存有关性欲的记录,结果表明,服用该药的女性能够更轻松地达到性高潮,并且对做爱的兴趣增加。

2019 ACOG实践简报:女性性功能障碍(No.213)

2019年7月,美国妇产科医师学会(ACOG)发布了女性性功能障碍管理指南,文章的主要目的是针对女性性功能障碍提供了一个概述,涉及最新的诊断标准以及最佳实践管理策略。

女性专用"粉色小药丸”进头条,疗效再次受质疑

女性专用“红色小药丸”再一次成为头条。“红色小药丸”的商品名为Addyi,适应症为女性性功能障碍,自诞生之日就饱受争议。